Legislature(2023 - 2024)BARNES 124
04/14/2023 03:15 PM House LABOR & COMMERCE
Note: the audio ![]()
and video ![]()
recordings are distinct records and are obtained from different sources. As such there may be key differences between the two. The audio recordings are captured by our records offices as the official record of the meeting and will have more accurate timestamps. Use the icons to switch between them.
| Audio | Topic |
|---|---|
| Start | |
| HB112 | |
| HB145 | |
| HB149 | |
| HB88 | |
| HB87 | |
| HB60 | |
| HB21 | |
| HB97 | |
| Adjourn |
* first hearing in first committee of referral
+ teleconferenced
= bill was previously heard/scheduled
+ teleconferenced
= bill was previously heard/scheduled
| *+ | HB 150 | TELECONFERENCED | |
| *+ | HB 145 | TELECONFERENCED | |
| + | TELECONFERENCED | ||
| += | HB 21 | TELECONFERENCED | |
| += | HB 60 | TELECONFERENCED | |
| += | HB 112 | TELECONFERENCED | |
| += | HB 149 | TELECONFERENCED | |
| += | HB 97 | TELECONFERENCED | |
| += | HB 87 | TELECONFERENCED | |
| += | HB 88 | TELECONFERENCED | |
HB 112-PROFESSION OF PHARMACY
3:18:07 PM
CHAIR SUMNER announced that the first order of business would be
HB 112, "An Act relating to the Board of Pharmacy; relating to
the practice of pharmacy; relating to pharmacies; relating to
prescription drug manufacturers; relating to prescriptions for
epinephrine; relating to the administration of epinephrine; and
providing for an effective date."
3:18:29 PM
REPRESENTATIVE RUFFRIDGE, as prime sponsor, stated that HB 112
is part of a multi-year process and has the support of the Board
of Pharmacy.
3:19:15 PM
The committee took a brief at-ease.
3:19:53 PM
REPRESENTATIVE PRAX moved to adopt Amendment 1 to HB 112,
labeled, 33-LS0600\A.1, Bergerud, 4/13/23, which read as
follows:
Page 1, line 2, following "manufacturers;":
Insert "relating to licensing and registration
requirements for certain wholesale drug distributors;"
Page 4, following line 11:
Insert a new bill section to read:
"* Sec. 4. AS 08.80.157(h) is amended to read:
(h) The board may suspend, revoke, deny, or
refuse to renew the license of a facility or pharmacy
on the following grounds:
(1) the finding by the board of violations
of a federal, state, or local law relating to the
practice of pharmacy, drug samples, wholesale or
retail drug or device distribution, or distribution of
controlled substances;
(2) a felony conviction under federal,
state, or local law of an owner of the facility or
pharmacy or of an employee of the facility or
pharmacy;
(3) the furnishing of false or fraudulent
material in an application made in connection with
drug or device manufacturing or distribution;
(4) suspension or revocation by federal,
state, or local government of a license currently or
previously held by the applicant for the manufacture
or distribution of drugs or devices, including
controlled substances;
(5) obtaining remuneration by fraud,
misrepresentation, or deception;
(6) dealing with drugs or devices that are
known or should have been known to be stolen drugs or
devices;
(7) dispensing or distributing drugs or
devices directly to patients by a wholesale drug
distributor other than a pharmacy unless
(A) the drug or device is a dialysate, drug
composed solely of fluids, electrolytes, and sugars,
or device that is
(i) necessary to perform home dialysis;
(ii) approved by the United States Food and
Drug Administration, as required by federal law; and
(iii) delivered in its original, sealed,
and labeled packaging only upon the receipt of a
physician's order; and
(B) the wholesale drug distributor
(i) delivers the dialysate drug or device
directly to a patient with end-stage renal disease, or
to the patient's designee, for the patient's self-
administration of dialysis therapy;
(ii) uses a bar code scanning and
verification system confirming that the dialysate drug
or device selected to fill the patient-specific order
matches the information on the patient-specific label;
and
(iii) has additional secondary accuracy and
delivery checks in place; and
(C) a licensed pharmacist serves as a
consultant to the wholesale drug distributor to
(i) conduct a retrospective audit of 10
percent of the dialysate drug and device orders
provided directly to patients processed by the
wholesale drug distributor every month; and
(ii) perform assessments at least twice
monthly to ensure quality of product storage,
handling, and distribution by the wholesale drug
distributor, and to ensure product expiration dates
are later than three months after the date of
assessment;
(8) violation of this chapter or a
regulation adopted under this chapter."
Renumber the following bill sections accordingly.
Page 9, line 20:
Delete "sec. 18"
Insert "sec. 19"
Page 9, line 21:
Delete "sec. 18"
Insert "sec. 19"
Page 9, line 31:
Delete "Section 20"
Insert "Section 21"
Page 9, following line 31:
Insert a new bill section to read:
"* Sec. 23. Section 4 of this Act takes effect
May 7, 2023."
Renumber the following bill section accordingly.
Page 10, line 1:
Delete "sec. 21"
Insert "secs. 22 and 23"
REPRESENTATIVE RUFFRIDGE objected for the purpose of discussion.
3:20:26 PM
REPRESENTATIVE PRAX explained that Amendment 1 would enable home
dialysis distributors to do so directly with the patient.
3:21:48 PM
REPRESENTATIVE RUFFRIDGE removed his objection to Amendment 1.
There being no further objection, Amendment 1 was adopted.
3:22:11 PM
REPRESENTATIVE RUFFRIDGE moved to report HB 112, as amended, out
of committee with individual recommendations and the
accompanying fiscal notes. There being no objection, CSHB
112(L&C) was reported from the House Labor and Commerce Standing
Committee.
| Document Name | Date/Time | Subjects |
|---|---|---|
| HB145 AKPIRG.pdf |
HL&C 4/14/2023 3:15:00 PM |
HB 145 |
| HB145 Chart.pdf |
HL&C 4/14/2023 3:15:00 PM |
HB 145 |
| Explanation of Changes HB145.pdf |
HL&C 4/14/2023 3:15:00 PM |
HB 145 |
| U.pdf |
HL&C 4/14/2023 3:15:00 PM |
HB 145 |